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Spatial and molecular mapping of Pfkelch13 gene 
polymorphism in Africa in the era of emerging 
Plasmodium falciparum resistance to artemisinin: 
a systematic review
Nadine K Kayiba, Doudou M Yobi, Evariste Tshibangu-Kabamba, Vo P Tuan, Yoshio Yamaoka, Brecht Devleesschauwer, Dieudonné M Mvumbi, 
Emile Okitolonda Wemakoy, Patrick De Mol, Georges L Mvumbi, Marie-Pierre Hayette, Angel Rosas-Aguirre, Niko Speybroeck
The spread of Plasmodium falciparum isolates carrying mutations in the kelch13 (Pfkelch13) gene associated with 
artemisinin resistance (PfART-R) in southeast Asia threatens malaria control and elimination efforts. Emergence of 
PfART-R in Africa would result in a major public health problem. In this systematic review, we investigate the 
frequency and spatial distribution of Pfkelch13 mutants in Africa, including mutants linked to PfART-R in southeast 
Asia. Seven databases were searched (PubMed, Embase, Scopus, African Journal Online, African Index Medicus, 
Bioline, and Web of Science) for relevant articles about polymorphisms of the Pfkelch13 gene in Africa before 
January, 2019. Following PRISMA guidelines, 53 studies that sequenced the Pfkelch13 gene of 23 100 sample isolates 
in 41 sub-Saharan African countries were included. The Pfkelch13 sequence was highly polymorphic (292 alleles, 
including 255 in the Pfkelch13-propeller domain) but with mutations occurring at very low relative frequencies. Non-
synonymous mutations were found in only 626 isolates (2·7%) from west, central, and east Africa. According to 
WHO, nine different mutations linked to PfART-R in southeast Asia (Phe446Ile, Cys469Tyr, Met476Ile, Arg515Lys, 
Ser522Cys, Pro553Leu, Val568Gly, Pro574Leu, and Ala675Val) were detected, mainly in east Africa. Several other 
Pfkelch13 mutations, such as those structurally similar to southeast Asia PfART-R mutations, were also identified, but 
their relevance for drug resistance is still unknown. This systematic review shows that Africa, thought to not have 
established PfART-R, reported resistance-related mutants in the past 5 years. Surveillance using PfART-R molecular 
markers can provide valuable decision-making information to sustain the effectiveness of artemisinin in Africa.
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Introduction
An estimated 219 million new malaria cases and 
435 000 deaths occurred globally in 2017, with more than 
75% of these cases coming from Africa.1 In the absence 
of an effective vaccine, reducing the burden of Plasmodium 
falciparum malaria relies on the effective ness of arte­
misinin­based com bination therapies (ACTs).1,2 ACTs 
combine the rapid antimalarial action (but short half­
life) of artemisinin or its derivatives with the slower 
action (but longer half­life) of partner drugs.3 However, 
one major challenge for malaria control and elimination 
efforts is the emergence and spread of P falciparum 
artemisinin resistance (PfART­R) from the Greater 
Mekong subregion in southeast Asia over the past 
decade.4–6
A reverse migration of PfART­R resistance towards 
Africa (by comparison with the evolutionary origin and 
spread of the parasite)7 is a troubling scenario that could 
have severe consequences on the burden of malaria 
because alternative therapies are few.8–10 As this resistance 
is not yet established in Africa, monitoring PfART­R 
on the continent is necessary from a global health 
perspective.9 Therapeutic efficacy trials are the standard 
method for assessing PfART­R; however, insufficient 
funding restricts these studies in African countries.3,11,12 
The delayed parasite clearance obtained in clinical trials 
and the in­vitro ring­stage (trophozoite) survival assay 
are also useful for tracking the emergence of artemisinin 
resistance.5,13–15
The association of specific single nucleotide poly­
morphisms (SNPs) in the P falciparum kelch 13 gene 
(Pfkelch13) with delayed parasite clearance has raised the 
potential of molecular markers for the surveillance of 
PfART­R.14,16,17 More than 100 Pfkelch13 mutations have 
been reported in Africa, but there is still little evidence 
of PfART­R mutants circulating in the continent.9,18 In 
this systematic review, we examine studies reporting 
Pfkelch13 SNPs across different African countries to 
determine the relative frequencies and spatial distri­
bution of parasites carrying mutations currently con­
sidered to be PfART­R markers.
Methods
Search strategy and selection criteria
Our systematic review follows the preferred reporting 
items for systematic reviews and meta­analyses (PRISMA) 
guidelines.19,20 Seven electronic medical data bases (Pub­
Med, Embase, Scopus, African Journal Online, African 
Index Medicus, Bioline, and Web of Science) were 
searched for peer­reviewed articles published before 
January, 2019, that have the relevant population, inter­
vention, comparator, outcomes, and study design (PICOS) 
framework (appendix p 2).
A predetermined search strategy used French and 
English versions of keyword terms of the Medical 
Subject Headings 2018 database and free terms, such 
as (“malaria” OR “falciparum” OR “paludisme”) AND 
(“marqueur moléculaire” OR “molecular marker” OR See Online for appendix
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“kelch13” OR “Pfkelch13” OR “K13” OR “PfK13”) AND 
(“Africa” OR “Afrique” OR each name of the 54 African 
countries) as detailed in appendix p 3). No filters or 
limitations (ie, language) ensured a large inclusion of 
informative reports. Individual searches on the internet 
allowed for the inclusion of references iden tified in primary 
reports. Inaccessible full­text articles were requested from 
corresponding authors. Although previous review papers 
were not included in the final analysis, they were sources 
for additional reports. Studies with data from an unknown 
sampling site or country, systematic reviews, modelling 
reports, reports based only on genetically modified isolates, 
conference pre sentations, abstracts with insufficient infor­
mation, and letters or corre spondence to editors were 
excluded.
Selection of studies, quality assessment, and data 
management
A structured data collection process addressed any 
possibility of uncertainty or missing data. Two masked 
teams (NKK, DYM, and AR­A; ET­K, VPT, and YY) worked 
independently at each stage of the process (literature 
search, relevance assessment, classification report and 
validation, and data extraction) before cross­checking and 
merging related outcomes. Extracted study variables 
included general information (authors, title of study, year 
of publication, geographical location of the study), study 
characteristics (study design, sampling period, collection 
time during the survey, participant characteristics, setting, 
sample size, and analytical methods), and SNP infor­
mation (loci sequenced, alleles found, number of isolates 
sequenced at specific loci, and number of isolates with 
individual alleles). The Newcastle­Ottawa scale assessed 
three quality criteria in selected studies: the representa­
tiveness of samples (maximum one star), the sample size 
(maximum one star), and the study outcome (maximum 
three stars).21 Regarding the outcome, the accurate 
definition of the genotype (given the reference), and the 
correct nomenclature of mutations following standard 
recommendations in molecular diagnostics22,23 awarded 
quality stars to articles. Only moderate (two to three stars) 
and high (four to five stars) quality studies were included 
in our systematic review.
Definitions
PfART­R is defined by a delayed parasite clearance re­
presenting partial resistance that affects only ring­stage 
parasites.17 PfART­R mutations are SNPs in the 
Pfkelch13­propeller domain associated with PfART­R in 
vitro or in vivo. Our systematic review uses the most 
updated list of 31 PfART­R molecular markers released by 
WHO in August, 2018,17 to classify PfART­R mutations 
into three categories. First, validated molecular markers 
significantly associated with both slow parasite clearance 
and reduced drug in­vitro sensitivity: Phe446Ile, Asn458Tyr, 
Met476Ile, Tyr493His, Arg539Thr, Ile543Thr, Pro553Leu, 
Arg561His, and Cys580Tyr. Second, candidate molecular 
markers significantly associated with slow parasite 
clearance: Pro441Leu, Gly449Ala, Cys469Phe, Ala481Val, 
Pro527His, Asn537Ile, Gly538Val, Val568Gly, Pro574Leu, 
Phe673Ile, and Ala675Val. Finally, molecular markers 
suspected to be associated with slow parasite clearance 
without reaching statistical significance because of the low 
number of mutants: Asp452Glu, Cys469Tyr, Lys479Ile, 
Arg515Lys, Ser522Cys, Asn537Asp, Arg575Lys, Met579Ile, 
Asp584Val, Pro667Thr, and His719Asn.
Mutations similar to molecular markers of PfART­R 
are also highlighted in this Review because they are 
structurally close to the WHO PfART­R mutations, 
although their clinical relevance is not yet established.
Data summary measures and synthesis
Since studies reporting Pfkelch13 SNPs had different 
designs and used mainly convenience sampling, their 
data were not suitable for combining in a meta­analytic 
approach. Sequencing processes provided variable 
lengths of genetic sequences resulting in diverse ranges 
of loci analysed for allele discovery in studies. A narrative 
synthesis was done to systematically organise the infor­
mation. SNPs in the Pfkelch13 sequence were defined on 
the basis of the reference wild­type Pfkelch13 sequence 
PF3D7_1343700, available in the UNIPROT protein 
database. Relative frequencies of each allele were 
summarised using the median values and interquartile 
ranges. Proportions of mutants with at least one 
non­synonymous change in the Pfkelch13 gene within 
each geographical site were calculated. Data from 
individual reports and locations were geo­referenced and 
locus­referenced before being uploaded on maps to 
display spatial and molecular patterns using the ggplot2,24 
ggmap,25 and rgdal26 packages in R (version 3.5.3).27 The 
risk of bias was minimised by excluding studies on 
malaria cases exported outside Africa and repeated 
communications on the same isolates.
Results
A list of 3756 records reporting individual SNPs in the 
Pfkelch13 gene were identified through database searching, 
including four records found manually. After removal of 
2236 duplicated reports, we screened 1520 records of 
which 1467 were considered ineligible according to 
the PICOS approach (figure 1). 53 studies remained after 
exclusion, with P falciparum sample isolates successfully 
sequenced for Pfkelch13 in 41 African countries;9,18,28–77 
baseline characteristics of these studies are detailed 
(appendix pp 4, 7). Analytical methods used in studies 
were nested PCR with subsequent Sanger sequencing 
(49 studies), next­generation sequen cing of targeted 
ampli cons (two studies), next­generation sequencing 
of whole P falciparum genomes with a genome­wide 
association study (one study), and mapping reads to 
targeted references (one study). Different proto cols were 
used in the exploration of SNPs in the Pfkelch13 gene, with 
sequence lengths ranging from 445 to 2438 base pairs. 
For the UNIPROT protein 
database see https://www.
uniprot.org/uniprot/Q8IDQ2
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44 studies identified both Pfkelch13 wild­type and mutant 
isolates, and nine found only wild­type isolates.
A total of 24 652 P falciparum isolates were analysed in 
the selected studies, yielding 23 100 isolates successfully 
sequenced at loci in the Pfkelch13 gene. The majority of 
isolates (22 474 isolates [97·3%]) carried a Pfkelch13 gene 
with either a wild­type sequence or a sequence displaying 
only synonymous mutations. The remaining 626 isolates 
(2·7%) had non­synonymous mutations, 604 (2·6%) of 
which were classified as missense substitutions in the 
amino acid sequence. Other non­synonymous mutations 
included 15 insertions (0·06%), four deletions (0·02%), 
and three nonsense substitutions (0·01%) (appendix p 8).
All the 41 African countries with information about 
Pfkelch13 polymorphisms were in sub­Saharan Africa 
(appendix p 9). Pfkelch13 non­synonymous mutations 
were absent in 11 countries: Botswana, Burundi, Guinea­
Bissau, Liberia, Mauritania, Sierra Leone, Somalia, South 
Africa, South Sudan, Sudan, and Zimbabwe. Sequence 
haplotypes were heterogeneous in the other 30 countries, 
with surveys detecting indistinct wild­type Pfkelch13 
and Pfkelch13 non­synonymous muta tions (at least a 
single isolate carrying a non­synonymous mutation). 
High (>50%) and intermediate (40–50%) relative pro­
portions of isolates with non­synonymous Pfkelch13 
mutations were reported in west Africa (Senegal and 
Nigeria) and east Africa (Kenya and Uganda; figure 2).
The majority of Pfkelch13 polymorphic loci (149 of 
182 [81·9%]) were detected in the propeller domain 
sequence (ie, downstream of codon position 440), with 
255 allelic variations (213 non­synonymous alleles) among 
a total of 292 alleles found in Pfkelch13 sequencing studies 
(figure 3). Lys189Thr was the most frequently reported 
non­synonymous allele in Pfkelch13 gene sequencing 
studies and Ala578Ser was the most frequently reported 
non­synonymous allele in partial sequencing studies of 
the Pfkelch13­propeller domain. Lys189Thr was observed 
in 145 mutants with relative frequencies in surveys 
ranging from 0·8% to 50% (median 32·8%), whereas 
Ala578Ser was reported in 98 mutants at relative 
frequencies in surveys from 0·2% to 7·1% (median 1·4%). 
Lys189Thr and Ala578Ser spanned over several countries 
at variable relative frequencies and there were no 
distinctive geographical patterns in their distribution 
(appendix p 10). Relative fre quencies of non­synonymous 
mutations in the Pfkelch13­propeller domain in surveyed 
sites ranged from 0·08% to 10·3% (appendix p 8).
Only 35 (0·15%) of the total 23 100 sequenced isolates 
recorded in this systematic review had alleles classified 
as candidate PfART­R markers by WHO: Cys469Tyr 
(Uganda),29,45 Arg515Lys (Zambia),9 Ser522Cys (Togo, 
Central African Republic, Gabon, DR Congo, Uganda, and 
Kenya),9,42,62,78 Val568Gly (Kenya),36 Pro574Leu (Rwanda),69 
and Ala675Val (Uganda and Rwanda).29,45,69 Moreover, 
WHO­validated PfART­R markers were found in at least 
one isolate in four countries: Phe446Ile (Mali),65 Met476Ile 
(Tanzania),47 and Pro553Leu (Kenya and Malawi; figure 4).77
16 alleles similar to WHO PfART­R markers were also 
found in 18 isolates (0·08% to 5·41% per sampling site) in 
seven countries: Gly449Asp and Gly449Ser (similar to 
Gly449Ala) in Mali,65,77 Cys469Trp (similar to Cys469Tyr) in 
Kenya,42 Met476Lys (similar to Met476Ile) in DR Congo,62 
Ser522Met and Ser522Arg (similar to Ser522Cys) in 
Togo, Uganda, and Kenya,36,64,78 Arg539Ile and Arg539Lys 
(similar to Arg539Thr) in Senegal and Kenya,36,70 Pro553Ile 
(similar to Pro553Leu) in Senegal,70 Arg561Cys (similar 
to ArgR561His) in Mali and DR Congo,9,77 Arg575Gly 
(similar to Arg575Lys) in Mali,65 Asp584Glu, Asp584Asn, 
and Asp584Tyr (similar to Asp584Val) in Comoros, Mali, 
and Kenya;36,44,65 and Pro667Arg and Pro667Ser (similar to 
Pro667Thr) in Kenya36 (appendix p 11). There has been an 
increasing trend in reports of PfART­R molecular markers 
Figure 1: Flowchart of the article selection process
Pfkelch13=Plasmodium falciparum kelch13. SNP=single-nucleotide polymorphisms. 
*PubMed (n=738), Scopus (n=101), Embase (n=754), African Index Medicus 
Database (n=1207), African Journals Online (n=10), Web of Science (n=926), 
Bioline (n=16).
3756 records identified
 2236 duplicated records excluded 
 
4 additional records
    identified through
    individual searches
    on the internet
3752 records identified through seven databases*
1520 records screened
1365 records unrelated to Pelch13 excluded
155 articles assessed for eligibility
53 articles included in the review
102 articles excluded
22 conference abstracts
3 correspondence to editors
2 reports with overlapping data
3 studies on isolates with
   experimentally induced mutations
4 reports on non-African migrant
    patients
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10 studies done outside Africa
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elch13 SNP information
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    origin
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elch13 











































Figure 2: Geographical maps 
displaying proportions of 
isolates carrying Pfkelch13 
with non-synonymous 
changes in Africa
Pie charts displayed on these 
maps represent the 
proportions of isolates 
with only synonymous 
changes in the Pfkelch13 gene, 
or with at least one 
non-synonymous change. 
Overall, isolates with 
non-synonymous changes 
were observed in sampling 
sites located within 
30 of 41 surveyed countries in 
east, west, and central Africa. 
Moderate-to-high 
proportions of isolates with 
non-synonymous changes in 
the Pfkelch13 sequence were 
found in east and west Africa. 
(A) Map showing surveys with 
only synonymous changes 
or wild-type isolates. 
(B) Map showing surveys 
with very low (>0% to <5%) 
proportions of isolates with 
non-synonymous Pfkelch13 
changes. (C) Low (5% to <10%) 
proportions of isolates 
with non-synonymous 
Pfkelch13 changes. 
(D) Moderate (10% to 20%) 




(>20% to <40%) 




(40 to <80%) proportions of 
isolates with non-synonymous 
Pfkelch13 changes.
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and mutations similar to PfART­R markers in Africa since 
the first year of reporting in 2014 (figure 5).
Discussion
This paper is the first comprehensive and systematic 
review specifically focusing on polymorphisms of the 
Pfkelch13 gene in Africa. Pfkelch13 has exclusively been 
explored in sub­Saharan African countries, showing a 
highly polymorphic structure with most allelic variations 
located in the propeller domain. Despite low relative 
frequencies of non­synonymous mutations in this do­
main across the continent, we identified mutant alleles 
reported to be associated with diminished artemisinin 
responsiveness in southeast Asia and several alleles 
structurally similar to resistance mutations.
The large allelic variation in the Pfkelch13­propeller 
domain (despite being located in a conserved region of the 
P falciparum genome) is likely to reflect the adaptation of 
parasites to selective pressures in Africa (eg, the use 
of antimalarial drugs).64,79 Therefore, this information 
should raise concerns among health policy makers to 
prevent the use of poor­quality (ie, counterfeit or sub­
standard) artemisinin­based thera pies and artemisinin 
mono therapies in Africa.79,80 Sub­therapeutic antimalarial 
drug concentrations would provide ideal conditions 
for selecting Pfkelch13­propeller mutants, among which 
PfART­R mutants could emerge.18,81 This hypothesis is 
supported by the generation of Pfkelch13­propeller muta­
tions in isolates with an African genetic background that 
under went in­vitro experimental arte misinin selective 
pressure, and the subsequent appearance of the PfART­R 
pheno type.14,82
Unlike the high frequency of non­synonymous muta­
tions in southeast Asia (with proportions ranging 
from intermediate to fixation levels among sequenced 
parasites),9 Pfkelch13 non­synonymous mutations in 
Africa occur at very low relative frequencies, despite 
presenting high allelic variation. The delayed introduction 
Figure 3: Molecular map of alleles in the 
Pfkelch13-propeller domain of African isolates
This figure shows allelic variations of amino acid residues within blades (1–6) of 
the Pfkelch13-propeller domain (after position 440) based on the 
Plasmodium falciparum 3D7 reference sequence. Of the 280 loci in this sequence, 
150 were polymorphic with synonymous and non-synonymous alleles. 
Loci reported with either a wild-type residue or synonymous mutations are 
shaded in yellow. Colours in cells identify whether the non-synonymous 
mutation is classified as PfART-R marker (red), a mutation mimicking a known 
PfART-R (dark blue), and a non-PfART-R marker (light blue). Single-letter 
abbreviations for the amino acid residues are as follows: A=alanine, C=cysteine, 
D=aspartic acid, E=glutamic acid, F=phenylalanine, G=glycine, H=histidine, 
I=isoleucine, K=lysine, L=leucine, M=methionine, N=aspargine, P=proline, 
Q=glutamine, R=arginine, S=serine, T=threonine, V=valine, W=tryptophan, and 
Y=tyrosine. In mutants, reference amino acids at specified locations were 
substituted with other amino acids—eg, M476I indicates that methionine at 
codon position 476 was replaced by isoleucine. The asterisk (*) shows a 
substitution of a reference amino acid residue by a stop-codon within the 
mutant (nonsense mutation). The underscore (_) shows deletion of a 
reference amino acid residue at a given codon-position within the 
mutant (deletion). PfART-R=Plasmodium falciparum artemisinin resistance. 
Wild-type residue or synonymous mutation
Non-synonymous mutation not classified by WHO as a PfART-R marker
Non-synonymous mutation classified by WHO as a PfART-R marker
























































P475 M476I M476K S477Y S477S T478P T478T K479 K480R A481
Y482S F483 G484R S485 A486 V487I L488S N489S S489K N489N
N490H N490S F491S L492 Y493Y V494A V494I V494L F495L G496G
G496S G497 N498I N499D N499O Y500Y D501G Y502 K503K A504G
A504T A504V L505F L505S F506 E507E T508 E509D E509E E509G
V510M V510_ V510V Y511 D512N R513R R513S L514 R515K D516
V517 W518C Y519C V520A S521 S522C S522M S522R S522S N523T
L524 N525 I526M  
P527 R528 R529K N530I N530K N530Y N531I N531N N531Y C532S
G533C G533S G533V V534A V534I V534L T535M T535T S536L N537
G538G R539I R539K R539R I540 Y541 C542G C542Y I543 G544R
G545E Y546 D547 G548D G548G G548S S549P S550 I551 I552M
S552C P553I P553L P553P A554S N554H N554K N554O N554S V555A
V555L E556K E556V A557S Y558C Y558H D559N H560L R561C M562T
K563 A564 W565* V566I E567E E567K V568G A569G A569S A569T
P570L L571 N572 T573A            
P574L R575G R575R S576L S577P A578D A578S M579 C580 V581F
V581V A582 F583L F583S F583Y D584E D584N D584Y N585K K586
N587K Y588C L589I V589I V589V I590F G591D G592E G592G G592R
G592V T593 N594 G595S E596G E596K E596R R597I R597R L598F
L598L N599 I601T E602D E602E E602 V603 Y604 E605G E606G
K607 M608L B609B N609L N609N K610K W611_ E612D E612G Q613E
Q613H                  
F614L P615S Y616N A617T A617V L618 L619S E620K A621A A621S
R622G R622I S623 S624 G625R A626P A626S A626T A626V A627
F628L N629T Y630P L631 N632 Q633R Q633* I634 Y635C V636
V637A V637D V637I V637_ G638R G639C G639S G639V I640V D641G
N642 E643 H644 N645 I646 L647 D648H S649 V650 E651
Q652 Y653 Q654Q P655 F656I N657 K658 R659 W660C Q661
F662 L663 N664 G665C G665S          
V666A V666I V666V T667R T667S E668 K669K K670 M671 N672
F673 G674 A675V A676S A676V T677A T677K L678V S679 D680N
S681 Y682 I683 I684 T685 G686 G687 E688 N689 G690C
G690G E691 V692 L693 N694 S695 C696 H697 F698F F699
S700 P701 D702 T703 N704 E705 W706 Q707 L708 G709
P710 S711 L712 L713 V714 P715 R716 F717 G718 H719
S720 V721 L722 I723 A724 N725 I726      
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of arte misinin in Africa between 2000 and 2005, asso­
ciated with a shorter time of drug pressure by comparison 
with the early use of artemisinin in southeast Asia since 
the 1970s, could explain why there is a scarcity of isolates 
with non­synonymous mutations in Africa.83 Moreover, 
multi­country studies done in Africa, southeast Asia, and 
South America had suggested that non­synonymous 
Pfkelch13 mutations reported in African countries could 
be due to local adaptation rather than to importation 
from Asia, because alleles were mostly Africa­specific 
Figure 4: Maps displaying sampling sites that recorded isolates carrying WHO PfART-R markers in Africa
Points plotted on these maps represent isolates carrying mutations associated with PfART-R in southeast Asia according to the WHO 2018 list of PfART-R 
markers.17 The point size is proportional to the number of isolates that were identified at each sampling location whenever it is known. Mutations with an 
unknown number of isolates are shown as crossed-out circles. (A) Map showing surveys that detected PfART-R markers validated by WHO in at least one isolate in 
four countries, including F446I in Mali, M476I in Tanzania, and P553L in Kenya and Malawi. (B–D) Maps showing surveys that recorded WHO candidate PfART-R 
markers including C469Y in Uganda, R515K in Zambia, S522C in Togo, Central African Republic, Gabon, DRC, Uganda, and Kenya, V568G in Kenya, P574L in Rwanda, 
and A675V in Uganda and Rwanda. Single-letter abbreviations for the amino acid residues are as follows: A=alanine, C=cysteine, F=phenylalanine, G=glycine, 
I=isoleucine, K=lysine, L=leucine, M=methionine, P=proline, S=serine, V=valine; and Y=tyrosine. Mutations show that reference amino acids at specified locations 
were substituted with other amino acids; for example, M476I indicates that a methionine at codon-position 476 was replaced by an isoleucine. 























































www.thelancet.com/infection   Vol 21   April 2021 e88
Review
and structurally different from those observed in 
southeast Asia .9,18,77
The WHO list of African Pfkelch13 alleles included nine 
non­synonymous mutations of the total 31 molecular 
markers of PfART­R based on studies done mainly in 
southeast Asia.17 Six of these mutations, namely 
Phe446Ile, Met476Ile, Pro553Leu, Val568Gly, Pro574Leu, 
and Ala675Val, were reported to be strongly associated 
with delayed parasite clearance in vivo.14,18,84,85 However, 
only Phe446Ile, Met476Ile, and Pro533Leu have shown a 
decreased response to artemisinin in vitro; they are being 
considered as validated artemisinin resistance markers by 
WHO.14,16,17,86 Ala675Val, although not listed as a validated 
marker, has shown an altered response to artemisinin in 
vitro in one clinical isolate from Uganda.45 Phe446Ile was 
only found in west Africa (Mali), where as Ala675Val, 
Met476Ile, Pro553Leu, Pro574Leu, and Val568Gly were 
reported in the Great Lakes region in east Africa (Kenya, 
Uganda, Malawi, Zambia, Tanzania, and Rwanda). The 
other three mutations identified in African isolates 
(Ser522Cys, Cys469Tyr, and Arg515Lys) could also be 
related to causing slow parasite clearance by artemisinin; 
however, according to the WHO, there is no significant 
evidence for this association because of the low number of 
these mutants in surveys.17 The Ser522Cys mutation 
that was found in several African countries (Mali, 
Gabon, Central African Republic, Togo, DR Congo, and 
Kenya),9,42,69,78 had been correlated with delayed parasite 
clearance in one (from southeast Asia) of the three unique 
mutant isolates that have been assessed in vivo (one 
isolate being from DR Congo).18,87 Similarly, two Cys469Tyr 
mutants have been linked to causing low parasite 
clearance and day 3 positive parasitaemia after treatment 
with artemisinin in southeast Asia.87,88 However,  in our 
systematic review, the unique African isolate with this 
mutation (from Uganda) assessed in vitro did not show a 
reduced response to artemisinin.45 Unlike Ser522Cys and 
Cys469Tyr, the data accumulated for the Arg515Lys 
mutation deserves to be taken into account in future lists 
of PfART­R markers as more than ten mutants from 
southeast Asia have been consistently associated with 
delayed parasite clearance.85,87,89
Nine non­synonymous mutations that are classified by the 
WHO as either validated, candidate, or suspected artemisinin 
resistance markers, and 245 other Pfkelch13­propeller 
mutations were registered during the writing of this 
Figure 5: Evolution in the reporting of PfART-R molecular markers during 2014–18
Graph shows the discovery of different PfART-R markers (shaded in red) and mutations similar to PfART-R markers (shaded in dark blue), over the time in Africa. 
The years 2014–18 indicate the publication year of the articles reporting mutants. Single-letter abbreviations for the amino acid residues are as follows: A=alanine, 
C=cysteine, D=aspartic acid, E=glutamic acid, F=phenylalanine, G=glycine, I=isoleucine, K=lysine, L=leucine, M=methionine, N=aspargine, P=proline, R=arginine, 
S=serine, T=threonine, V=valine, W=tryptophan, and Y=tyrosine. In mutant alleles, reference amino acids at specified locations were substituted with other amino 
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syste matic review. Most of them have never been 
experimentally explored because they did not fulfil 
the criteria for further functional exploration (eg, high 
frequency of new alleles with non­synonymous mutation, 
evidence of allele dissemination, or pre liminary association 
with clinical resistance).9 16 amino acid substitutions 
among the unexplored mutations found in this review are 
structurally close to the WHO PfART­R mutations—ie, 
Gly449Asp, Gly449Ser, Cys469Trp, Met476Lys, Ser522Met, 
Ser522Arg, Arg539Ile, Arg539Lys, Prp553Ile, Arg561Cys, 
Arg575Gly, Asp584Glu, Asp584Asn, Asp584Tyr, Thr677Arg, 
and Thr677Ser. For instance, Gly449Asp and Gly449Ser 
observed in Mali65 are able to resemble the PfART­R 
mutation Gly449Ala. They occur on a locus known to be 
accessible to glycine (Gly449) and establish a network of 
hydrogen bonds for the Pfkelch13 protein function.90 These 
two African alleles could be structurally unfavourable to the 
structure of the Pfkelch13 propeller domain, resulting in 
potential markers for PfART­R.90 Molecular modelling can 
thus provide more information about the phenotypic 
effect of unexplored mutations on the Pfkelch13 protein 
structure;9,90 however, conventional research (in vitro or in 
vivo studies using either transgenic or clinical parasites) is 
always required to confirm their functional importance. 
Until the functional effect of these mutations that are 
similar to PfART­R markers is clarified, we suggest that 
they are included in any molecular surveillance of PfART­R 
in Africa when possible.
It is important to mention that African parasites might 
have their own genetic background preference to select 
PfART­R that would differ from parasites in southeast 
Asia.8,91 The discovery of Pfcoronin in 2018 as a second 
PfART­R gene suggests that non­Pfkelch13 types of 
resistance could independently emerge in natural settings 
in Africa.92–94 Pfcoronin mutants associated with PfART­R 
were selected among parasites of Senegalese origin, using 
the same in­vitro selection experiment that had related 
Pfkelch13 mutations to reduced artemisinin susceptibility 
in Tanzanian parasites.14,90,92 Although the Pfcoronin muta­
tions are not yet detected in clinical isolates, their structural 
similarity with Pfkelch13 provides insights into the 
molecular mechanisms of artemisinin resistance.93–95 
Tracking the emergence of Pfkelch13 mutant parasites in 
Africa is very important, but further research is needed to 
identify other possible PfART­R genes.91
Our systematic review has several limitations. First, no 
information is available from non­endemic malaria 
areas—eg, the Maghreb countries (eg, Algeria, Libya, 
Morocco, Egypt, Western Sahara, and Tunisia)—that 
have a lot of migration from sub­Saharan Africa, where 
the PfART­R threat might also exist. Future surveys 
should fill in the gaps of the existing map. Second, the 
heterogeneity in survey designs, sampling methods 
(eg, convenience samples), and analytical approaches 
in individual studies (eg, different lengths of analysed 
Pfkelch13 sequences, different sampling time in surveys) 
did not allow pooling of reports for a standard 
meta­analysis. Third, primary information (eg, the 
precise collection time) was very variable or not available 
in some surveys, hindering the possibility of analysing 
temporal trends. Instead, we assessed the temporal trend 
of reporting PfART­R mutations. Fourth, the inaccuracy 
in the number of isolates carrying alleles in some 
reviewed studies and mutations reported with unknown 
origin that were excluded from the review could have led 
to an underestimation of allele frequencies (eg, Pro553Leu 
in Malawi77 or Phe446Ile in Mali65). For these studies, the 
frequency of sites with these mutations was reported 
without assigning allele frequencies. Finally, our review 
did not include studies reporting migrating patients who 
returned to their home countries from Africa with 
isolates carrying Pfkelch13 mutations. For instance, three 
PfART­R markers (Cys580Tyr, Met579Ile, and Arg539Thr) 
found in isolates of patients returning to Asia from 
Africa were excluded from this Review.96,97 These 
mutations that favour PfART­R were probably acquired 
outside Africa as no autochthonous patients had 
these mutations, despite published reports extensively 
discussing that acquisition in Africa cannot be ruled out.
Despite the limitations above, we believe that our 
systematic review provides a valuable baseline reference 
for building and strengthening surveillance activities in 
African countries to prevent the emergence and later 
spread of PfART­R. The message in this paper is not a 
lack of confidence in ACTs, which are still very effective in 
Africa, but it is more a call for vigilance and increased 
surveillance efforts against possible PfART­R emergence 
locally. Therefore, proactive surveillance using PfART­R 
molecular markers and timely consolidation and inter­
pretation of surveillance findings can contribute to 
decision making to further sustain the effectiveness of 
artemisinin in Africa. Any possible introduction by 
known PfART­R alleles, temporal increase in the fre­
quency of autochthonous alleles, and expansion of non­
synonymous mutations similar to PfART­R markers 
should be targeted by surveillance efforts. Enhanced 
research efforts (ie, more funding and field exploration) 
are required to uncover the functional importance of 
other Pfkelch13­propeller mutations and to identify other 
possible PfART­R genes like Pfcoronin.
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